Injectable drug delivery is defined as introduction of a drug or drugs in the patient by using a delivery device. Injectables allow the transport of drugs formulated in liquid form, directly in the body. Even though, they may be designed to transport the drug to specific part of the body. Such drug delivery technology by the use of injections is majorly segmented into devices and formulations.Based on product, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self injection devices, and others (microneedles, nanoneedles and blunt needle injections), while injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations.
The Injectable Drug Delivery Market valued as a 15.90 billion USD market in 2012 and is expected to show a CAGR of about 17.55% and is expected to reach 41.94 billion USD by the end of the year 2017.
The Market is basically segmented into four categories namely on the basis of formulation, devices, application and geographical basis. Based on formulation the market is segmented into categories which are Conventional drug delivery and Novel Drug Delivery. On the basis of devices the market is segmented into categories which are Conventional devices and self injectable devices. On the basis of application the market can be segmented into categories like Oncology, Diabetes, Hep C and others, etc. The market analysis is also provided for different geographical areas which include North America, Europe, APAC and rest of the world.
The major factors which drive the market growth are technological advances and increasing demand for devices. The major limitations are injuries and infections due to Injectables and regulatory framework issues.
The major players in this market are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation and West Pharmaceutical Inc.